Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium

CME: 1.0

Target Audience

This online activity is targeted to practitioners who are involved in treating patients with MGD-associated DED, such as optometrists, ophthalmologists, nurse practitioners, physician assistants, and nurses.

Activity Overview

Meibomian gland dysfunction (MGD) is one of the most common causes of dry eye disease (DED), which can profoundly impact patients and their quality of life. Although many treatment options are available, no pharmacologic treatment has yet been approved by the United States Food and Drug Administration specifically for MGD. Several agents are currently in development with novel mechanisms of action.

This Community Practice Connections™ program provides an in-depth review of key highlights from a live satellite symposium held adjunct to the AOA/AOSA 2022 Optometry’s Meeting in June. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with MGD, putting recent clinical trial data into context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Evaluate the burden of disease associated with MGD-associated DED
  • Review the safety and efficacy data surrounding currently available therapies used for the treatment of MGD-associated DED
  • Evaluate the mechanisms of action of investigational agents for the treatment of MGD-associated DED
  • Analyze clinical trial data for agents being investigated for the treatment of MGD-associated DED

Post a comment to this article